Abstract
Understanding the molecular consequences of variants which introduce premature termination codons (PTCs) is essential to predicting their clinical impact1. Although transcripts with PTCs are generally expected to undergo nonsense-mediated mRNA decay (NMD)2–4, up to 45% of all possible PTCs in the human genome are predicted to escape NMD5. Existing studies of constraint against predicted loss-of-function variants at the transcript level6–10 do not account for regional differences in NMD efficiency. Here, we developed an NMD-informed constraint metric using sequencing data from 730,947 individuals and found 2,764 transcripts with regional nonsense constraint. In rare disease cohorts, de novo nonsense and frameshift variants in constrained regions are up to 9.4-fold enriched and associated with up to 6.4-fold higher odds of diagnosis than in unconstrained regions. We prioritise fourteen candidate disease genes in which constrained regions harbour clusters of nonsense and frameshift variants. These findings will enhance variant interpretation, deliver mechanistic insights, and empower the discovery of novel disease genes.
Competing Interest Statement
NW receives research funding from Novo Nordisk. All other authors declare no conflicts of interest.
Funding Statement
AB is supported by a Wellcome PhD Training Fellowship for Clinicians and the 4Ward North PhD Programme for Health Professionals (223521/Z/21/Z). NW is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant no. 220134/Z/20/Z) and a research prize from the Lister Institute. CAJ acknowledges support from MRC project grant MR/T017503/1. SB acknowledges the support of the NIHR Manchester Biomedical Research Centre. This study has been delivered through the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Genomics England has ethical approval from the HRA Committee East of England Cambridge South (REC Ref 14/EE/1112). This specific project was approved for publication by the Genomics England Research Registry (RR589)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos